Figure 3.

Participant preferences: (a) Leukocytosis/response on symptoms only: full control of systemic symptoms may be achieved in the patient receiving ruxolitinib, even in the presence of uncontrolled myeloproliferation (persistence of splenomegaly, hyperleukocytosis). If so, which therapeutic approach would you consider? (b) Splenomegaly due to failure to respond to adequate or maximum tolerated dose (resistance): how do you manage the problem of primary resistance splenomegaly or loss of response to ruxolitinib?